566 related articles for article (PubMed ID: 17007735)
1. Animal models of Huntington's disease: implications in uncovering pathogenic mechanisms and developing therapies.
Wang LH; Qin ZH
Acta Pharmacol Sin; 2006 Oct; 27(10):1287-302. PubMed ID: 17007735
[TBL] [Abstract][Full Text] [Related]
2. Experimental models of HD and reflection on therapeutic strategies.
Kim J; Bordiuk OL; Ferrante RJ
Int Rev Neurobiol; 2011; 98():419-81. PubMed ID: 21907096
[TBL] [Abstract][Full Text] [Related]
3. Towards a transgenic model of Huntington's disease in a non-human primate.
Yang SH; Cheng PH; Banta H; Piotrowska-Nitsche K; Yang JJ; Cheng EC; Snyder B; Larkin K; Liu J; Orkin J; Fang ZH; Smith Y; Bachevalier J; Zola SM; Li SH; Li XJ; Chan AW
Nature; 2008 Jun; 453(7197):921-4. PubMed ID: 18488016
[TBL] [Abstract][Full Text] [Related]
4. Pathogenic mechanisms in Huntington's disease.
Jones L; Hughes A
Int Rev Neurobiol; 2011; 98():373-418. PubMed ID: 21907095
[TBL] [Abstract][Full Text] [Related]
5. The use of transgenic and knock-in mice to study Huntington's disease.
Hickey MA; Chesselet MF
Cytogenet Genome Res; 2003; 100(1-4):276-86. PubMed ID: 14526189
[TBL] [Abstract][Full Text] [Related]
6. Mouse models of Huntington's disease.
Menalled LB; Chesselet MF
Trends Pharmacol Sci; 2002 Jan; 23(1):32-9. PubMed ID: 11804649
[TBL] [Abstract][Full Text] [Related]
7. Derivation of Huntington's disease-affected human embryonic stem cell lines.
Bradley CK; Scott HA; Chami O; Peura TT; Dumevska B; Schmidt U; Stojanov T
Stem Cells Dev; 2011 Mar; 20(3):495-502. PubMed ID: 20649476
[TBL] [Abstract][Full Text] [Related]
8. Autopsy-proven Huntington's disease with 29 trinucleotide repeats.
Kenney C; Powell S; Jankovic J
Mov Disord; 2007 Jan; 22(1):127-30. PubMed ID: 17115386
[TBL] [Abstract][Full Text] [Related]
9. Weight loss in Huntington disease increases with higher CAG repeat number.
Aziz NA; van der Burg JM; Landwehrmeyer GB; Brundin P; Stijnen T; ; Roos RA
Neurology; 2008 Nov; 71(19):1506-13. PubMed ID: 18981372
[TBL] [Abstract][Full Text] [Related]
10. The clinical and genetic features of Huntington disease.
Sturrock A; Leavitt BR
J Geriatr Psychiatry Neurol; 2010 Dec; 23(4):243-59. PubMed ID: 20923757
[TBL] [Abstract][Full Text] [Related]
11. Transgenic animal models for study of the pathogenesis of Huntington's disease and therapy.
Chang R; Liu X; Li S; Li XJ
Drug Des Devel Ther; 2015; 9():2179-88. PubMed ID: 25931812
[TBL] [Abstract][Full Text] [Related]
12. Development of novel therapies for Huntington's disease: hope and challenge.
Qin ZH; Wang J; Gu ZL
Acta Pharmacol Sin; 2005 Feb; 26(2):129-42. PubMed ID: 15663888
[TBL] [Abstract][Full Text] [Related]
13. Transgenic rat model of Huntington's disease.
von Hörsten S; Schmitt I; Nguyen HP; Holzmann C; Schmidt T; Walther T; Bader M; Pabst R; Kobbe P; Krotova J; Stiller D; Kask A; Vaarmann A; Rathke-Hartlieb S; Schulz JB; Grasshoff U; Bauer I; Vieira-Saecker AM; Paul M; Jones L; Lindenberg KS; Landwehrmeyer B; Bauer A; Li XJ; Riess O
Hum Mol Genet; 2003 Mar; 12(6):617-24. PubMed ID: 12620967
[TBL] [Abstract][Full Text] [Related]
14. Mechanisms of neuronal cell death in Huntington's disease.
Sawa A; Tomoda T; Bae BI
Cytogenet Genome Res; 2003; 100(1-4):287-95. PubMed ID: 14526190
[TBL] [Abstract][Full Text] [Related]
15. Genetics and neuropathology of Huntington's disease.
Reiner A; Dragatsis I; Dietrich P
Int Rev Neurobiol; 2011; 98():325-72. PubMed ID: 21907094
[TBL] [Abstract][Full Text] [Related]
16. Molecular mediators, environmental modulators and experience-dependent synaptic dysfunction in Huntington's disease.
Hannan AJ
Acta Biochim Pol; 2004; 51(2):415-30. PubMed ID: 15218539
[TBL] [Abstract][Full Text] [Related]
17. Dysregulation of synaptic proteins, dendritic spine abnormalities and pathological plasticity of synapses as experience-dependent mediators of cognitive and psychiatric symptoms in Huntington's disease.
Nithianantharajah J; Hannan AJ
Neuroscience; 2013 Oct; 251():66-74. PubMed ID: 22633949
[TBL] [Abstract][Full Text] [Related]
18. Huntington's disease: clinical presentation and treatment.
Novak MJ; Tabrizi SJ
Int Rev Neurobiol; 2011; 98():297-323. PubMed ID: 21907093
[TBL] [Abstract][Full Text] [Related]
19. Clinico-pathological rescue of a model mouse of Huntington's disease by siRNA.
Wang YL; Liu W; Wada E; Murata M; Wada K; Kanazawa I
Neurosci Res; 2005 Nov; 53(3):241-9. PubMed ID: 16095740
[TBL] [Abstract][Full Text] [Related]
20. Screening of therapeutic strategies for Huntington's disease in YAC128 transgenic mice.
Gil-Mohapel JM
CNS Neurosci Ther; 2012 Jan; 18(1):77-86. PubMed ID: 21501423
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
